

Advising the Congress on Medicare issues

Producing comparative effectiveness information

Nancy Ray and Hannah Neprash April 9, 2008

MECIPAC

Overview

- Public and private health expenditures are substantial and growing
- Little information available that compares clinical effectiveness of alternate healthcare services
- Many new services disseminate quickly into routine medical care with little or no basis for providers knowing whether they outperform existing treatments, and to what extent



Previous work by Commission on comparative effectiveness

- Recommended an independent entity sponsor and disseminate comparative-effectiveness information
- Entity would:
 - Be independent
 - Have a stable and secure source of funding
 - Produce objective information under a transparent process
 - Seek input on agenda items
 - Disseminate information to patients, providers, and payers
 - Have no role in making or recommending coverage or payment decisions



Current analysis focuses on governance


- Establishing a board
- Structuring a comparative-effectiveness entity
- Funding



Establishing a comparative-effectiveness board


- Participation by individuals from the public and private sector
- Level of involvement
 - Periodic guidance versus day-to-day oversight of research and communication activities
 - Part-time versus full-time commitment
- Conflicts of interest

Full-time board provides day-to-day oversight of a comparative-effectiveness entity





Part-time board provides periodic guidance of a comparative-effectiveness entity





Other issues about establishing a board

- Appointment process
- Duration of appointments
- Frequency and setting of meetings



Structuring a comparative-effectiveness entity

- Alternatives vary in their closeness to the federal government and private sector
 - FFRDC—private sector organization under contract to an HHS agency
 - Independent executive branch agency
 - Independent legislative branch agency
 - Congressionally-chartered nonprofit organization
- All options would have a board overseeing research activities

Funding should be stable, public-private, and broad-based

- Comparative effectiveness trust fund
 - Public-private
 - Broad-based
 - Stable and secure
- Examples of funding source:
 - Percentage of the Medicare Part A trust fund + levy on private sector organizations
 - General revenues



For discussion

- Establishing a board
- Structuring a comparative-effectiveness entity
- Funding

